Ahammune Biosciences raises $5 million to fund novel vitiligo therapy

The funding will enable the company in conducting Phase II human clinical trials for its potential drug candidate for vitiligo - an autoimmune disease that causes the loss of skin colour. Vitiligo has no cure.